4D Molecular Therapeutics (NASDAQ:FDMT) Earns Buy Rating from Chardan Capital

Key Points

• 4D Molecular Therapeutics received a reiterated "buy" rating from Chardan Capital, with a price target of $25.00, indicating a potential upside of 352.08% from its previous close.
• Goldman Sachs and Barclays both lowered their price targets for the stock, while Weiss Ratings issued a "sell (d-)" rating, reflecting mixed analyst sentiment.
• 4D Molecular Therapeutics reported a quarterly loss of ($0.98) EPS, missing analyst estimates and facing negative returns on equity and margins.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at Chardan Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $25.00 target price on the stock. Chardan Capital's price objective points to a potential upside of 244.35% from the company's previous close. Chardan Capital also issued estimates for 4D Molecular Therapeutics' FY2025 earnings at ($3.52) EPS.

Several other research firms also recently issued reports on FDMT. Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Tuesday, July 29th. Barclays dropped their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Finally, The Goldman Sachs Group reduced their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $30.40.

4D Molecular Therapeutics Stock Performance

NASDAQ FDMT traded up $0.16 during trading hours on Tuesday, hitting $7.26. 1,110,187 shares of the company traded hands, compared to its average volume of 2,423,758. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $17.41. The stock has a market capitalization of $339.04 million, a price-to-earnings ratio of -2.06 and a beta of 2.83. The business's 50-day moving average is $4.68 and its 200-day moving average is $4.14.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million. Analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd bought a new stake in 4D Molecular Therapeutics during the 1st quarter worth approximately $39,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of 4D Molecular Therapeutics during the first quarter worth $41,000. Los Angeles Capital Management LLC purchased a new stake in shares of 4D Molecular Therapeutics during the second quarter worth $42,000. Quadrature Capital Ltd purchased a new stake in shares of 4D Molecular Therapeutics during the second quarter worth $42,000. Finally, AQR Capital Management LLC purchased a new stake in shares of 4D Molecular Therapeutics in the first quarter worth $46,000. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.